Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva’s Cinqair To Join Nucala For Severe Asthma After FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approved the interleukin-5 antagonist reslizumab March 23 for the treatment of severe asthma in patients 18 and older who have an eosinophilic phenotype.

You may also be interested in...



US FDA Rejection Stings Nucala In COPD; New Study May Be Needed

Mepolizumab would be first drug for chronic obstructive pulmonary disorder to use eosinophil count as a biomarker, but FDA’s complete response letter says more clinical data are needed.

Enhertu Poised To Rewrite The Standard Of Care After ESMO

AstraZeneca/Daiichi Sankyo's Enhertu is poised to become the new standard of care for second-line HER2-positive breast cancer after handedly beating Roche's Kadcyla on PFS.

Wet AMD Market Snapshot: A High-Growth Market Poised For Change

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel